Drug Development
Alzamend Neuro Advances Innovative Therapies for Mental Health Disorders
Alzamend Neuro is developing novel therapeutic approaches for challenging neurological and psychiatric conditions, including Alzheimer's, Bipolar Disorder, Major Depressive Disorder, and PTSD. The company's pioneering treatments aim to improve patient outcomes by addressing current treatment limitations.
Alzamend Neuro Launches Phase II Trial for Innovative Lithium-Based Alzheimer's Therapy
Alzamend Neuro has initiated a Phase II clinical trial for AL001, a novel lithium therapy targeting multiple neuropsychiatric conditions, with potential to improve brain drug delivery and reduce side effects.
RNA Pioneer Dr. Phillip Zamore Joins TransCode Therapeutics' Scientific Advisory Board
TransCode Therapeutics has appointed Dr. Phillip D. Zamore, a leading RNAi researcher, to its Scientific Advisory Board, potentially strengthening the company's oncology research capabilities and RNA therapeutic development strategies.
RNAi Pioneer Dr. Phillip Zamore Joins TransCode Therapeutics' Scientific Advisory Board
TransCode Therapeutics strengthens its scientific leadership by appointing renowned RNA interference expert Dr. Phillip Zamore to its Scientific Advisory Board, potentially boosting the company's cancer therapeutic research capabilities.
Creative Biolabs Expands CAR-T Therapy Development with Comprehensive CDMO Services
Creative Biolabs is offering end-to-end solutions for CAR-T therapy development, providing comprehensive services from plasmid design to viral vector manufacturing, potentially accelerating personalized cancer treatment research.
NanoViricides Highlights Potential Antiviral Solution Amid Changing COVID Booster Recommendations
NanoViricides' President Dr. Anil Diwan comments on the FDA's updated COVID-19 booster policy, emphasizing the need for alternative antiviral treatments and positioning the company's NV-387 drug candidate as a potential solution for respiratory viral infections.
Quantum BioPharma Advances Multiple Sclerosis Drug Toward Clinical Trials
Quantum BioPharma has signed an agreement with a contract research organization to prepare an Investigational New Drug application for Lucid-21-302, a potential breakthrough therapy for multiple sclerosis that could prevent neurological damage.
Creative Biolabs Unveils Advanced Bispecific Antibody Platform at Industry Conference
Creative Biolabs demonstrates cutting-edge bispecific antibody technology with potential to revolutionize cancer immunotherapy, showcasing customized development capabilities and innovative research approaches.
NanoViricides Advances Broad-Spectrum Antiviral Drug, Eyes Multiple Phase II Trials
NanoViricides is progressing its NV-387 drug candidate across multiple viral infections, with pending Phase II trials for MPox and emerging programs for measles and avian flu, highlighting significant potential in antiviral treatment development.
NanoViricides Advances Promising Antiviral Drug Against Measles and MPox
NanoViricides is developing NV-387, a potential breakthrough treatment for Measles and MPox amid rising global case counts and limited medical interventions. The drug represents a critical advancement in addressing urgent infectious disease challenges.
Silo Pharma Advances PTSD Treatment with FDA-Requested Safety Study
Silo Pharma is conducting a critical safety study on its intranasal PTSD treatment SPC-15, which could potentially provide a new therapeutic option for patients struggling with stress-related disorders by meeting FDA requirements for clinical advancement.
CNS Pharmaceuticals Raises $5 Million in Public Offering to Advance Brain Cancer Research
CNS Pharmaceuticals secures $5 million in funding through a public offering, aimed at supporting the development of innovative brain cancer treatments, with a focus on its lead drug candidate Berubicin.
Annovis Bio Advances Alzheimer's Treatment with Phase 3 Clinical Trial
Annovis Bio has initiated a pivotal Phase 3 clinical trial for buntanetap, a potential treatment for early Alzheimer's disease, with the potential to address symptomatic and disease-modifying aspects of the condition.
Clene Inc. Advances CNM-Au8 Toward Potential Accelerated Approval for ALS
Clene Inc. reports promising progress on its CNM-Au8 therapy for ALS, with plans to submit a New Drug Application under the FDA's Accelerated Approval pathway, supported by significant survival data and reduced expenses.
Clene Inc. Advances Promising Therapy for ALS, Targets Accelerated FDA Approval
Clene Inc. reports significant progress on CNM-Au8, a potential breakthrough therapy for amyotrophic lateral sclerosis (ALS), with plans to submit a New Drug Application under the FDA's Accelerated Approval pathway in Q4 2025. New data demonstrates improved patient survival and neurological repair.
TransCode Therapeutics Advances RNA Cancer Therapy, Reaches Milestone in Phase 1a Trial
TransCode Therapeutics has successfully dosed 15 patients in its Phase 1a trial for RNA-based cancer therapeutic TTX-MC138, with early data showing promising target engagement and no significant toxicities.
Pacylex Pharmaceutical Explores N-myristoyltransferase Inhibitors as Potential ADC Cancer Therapies
Pacylex Pharmaceuticals is presenting innovative research on N-myristoyltransferase (NMT) inhibitors as potential payloads for antibody drug conjugates (ADCs), highlighting promising early clinical results in cancer treatment across multiple tumor types.
NanoViricides to Present at D. Boral Capital Inaugural Global Conference, Highlighting Antiviral Drug Development
NanoViricides, a clinical-stage biotech company specializing in nanomedicine-based antiviral treatments, will participate in the D. Boral Capital Inaugural Global Conference, offering investors insights into its advanced drug candidates targeting respiratory viral infections and other diseases.
NanoViricides Advances Measles Drug Development with Promising Broad-Spectrum Antiviral
NanoViricides is developing NV-387, a broad-spectrum antiviral drug candidate targeting measles amid declining vaccination rates. The drug shows potential for addressing infectious disease challenges with its unique therapeutic approach.
Tonix Pharmaceuticals Reveals Promising Preclinical Data for Cancer Immunotherapy TNX-1700
Tonix Pharmaceuticals presented positive preclinical results for TNX-1700, a fusion protein showing potential in reducing immunosuppressive cells and enhancing anti-tumor immune responses in gastric cancer models, particularly when combined with anti-PD1 therapy.
Annovis Bio Bolsters Neurodegenerative Research with Key Biostatistics Appointment
Annovis Bio strengthens its scientific team by appointing Hui Liu as Director of Biostatistics, enhancing its capabilities in clinical trial design and data analysis for neurodegenerative disease research.
Kairos Pharma to Present Promising Cancer Treatment Data at 2025 ASCO Meeting
Kairos Pharma will showcase new research on KROS 101, a small molecule GITR ligand agonist, potentially offering insights into innovative cancer treatment approaches at the prestigious ASCO Annual Meeting.
Soligenix Advances Promising Skin Cancer Treatment with 75% Response Rate
Soligenix's HyBryte™ therapy shows significant potential in treating cutaneous T-cell lymphoma, with a 75% response rate in a federally supported clinical trial. The innovative, light-activated treatment could offer new hope for patients with this rare form of skin cancer.
Kairos Pharma Receives DoD Grant to Advance Lung Cancer Biomarker Research
Kairos Pharma secures a Department of Defense grant to support its innovative cancer research, focusing on developing ENV105, a potential breakthrough in addressing drug resistance in prostate and lung cancers.
Soligenix's HyBryte™ Demonstrates Promising Results in Rare Skin Cancer Treatment
A novel skin cancer therapy shows a 75% response rate in treating cutaneous T-cell lymphoma, offering potential hope for patients with limited treatment options. The treatment's safety profile and rapid results could significantly impact rare cancer care.
Zelenirstat Shows Promise in Disrupting Triple-Negative Breast Cancer Cell Growth
Pacylex Pharmaceuticals' lead drug zelenirstat demonstrates potential to disrupt mitochondrial function in triple-negative breast cancer cells, potentially offering new insights into cancer treatment strategies.
Calidi Biotherapeutics Receives FDA Clearance for Innovative Cancer Treatment Trial
Biotech firm Calidi Biotherapeutics has obtained FDA approval to begin clinical trials of CLD-201, a novel stem cell-based virotherapy targeting solid tumors. The therapeutic approach combines adipose-derived stem cells with oncolytic vaccinia virus, potentially offering a breakthrough in treating challenging cancer types.